Information de reference pour ce titreAccession Number: | 01445436-201410010-00002.
|
Author: | Fichter, Christiane Daniela 1,2; Timme, Sylvia 1; Braun, Julia Alexandra 1; Gudernatsch, Verena 1; Schopflin, Anja 1; Bogatyreva, Lioudmilla 3; Geddert, Helene 4; Faller, Gerhard 4; Klimstra, David 5; Tang, Laura 5; Hauschke, Dieter 3; Werner, Martin 1,6,7; Lassmann, Silke 1,6,7,8
|
Institution: | (1)Department of Pathology, University Medical Center, Freiburg, Germany (2)Faculty of Biology, University of Freiburg, Freiburg, Germany (3)Institute of Medical Biometry and Medical Informatics, University Medical Center, Freiburg, Germany (4)Department of Pathology, St. Vincentius-Kliniken, Karlsruhe, Germany (5)Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA (6)Comprehensive Cancer Center Freiburg, University Medical Center, Freiburg, Germany (7)German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (8)BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany
|
Title: | |
Source: | International Journal Of Cancer. 135(7):1517-1530, October 1, 2014.
|
Abstract: | : Receptor tyrosine kinases (RTKs) are in the focus of targeted therapy for epithelial tumors. Our study addressed the role of EGFR, HER2 and HER3 expression and dimerization in esophageal cancers in situ and in vitro in the context of therapeutic EGFR and HER2 inhibitors. In archival pretreatment biopsies of esophageal carcinomas (n = 110), EGFR was preferentially expressed in esophageal squamous cell carcinomas (ESCCs) (22.4%; p = 0.088) and HER2 (34.4%; p < 0.001) with HER3 (91.5%; p < 0.001) in esophageal (Barrett's) adenocarcinomas (EACs). In situ proximity ligation assays revealed mainly EGFR and HER2 homodimers in ESCC and EAC cases, respectively. However, EAC cases also exhibited HER2/HER3 heterodimers. In vitro ESCC (OE21) cells displayed a significant response to erlotinib, gefitinib and lapatinib, with loss of AKT phosphorylation, G0/G1 cell cycle arrest and induction of apoptosis. In EAC cells (OE19, OE33 and SK-GT-4), lapatinib was similarly effective in strongly HER2-positive (mainly HER2 homodimers and some HER2/EGFR heterodimers) OE19 and OE33 cells. The HER2-targeting antibodies (trastuzumab and pertuzumab) given alone were largely ineffective in ESCC and EAC cells. However, both antibodies significantly induced antibody-dependent cellular cytotoxicity in EAC (OE19 and OE33) cells upon co-culture with peripheral blood mononuclear cells. The study reveals that overexpression of EGFR and HER2 predominantly results in homodimers in ESCCs and EACs, respectively. Still, some EACs also show HER2 dimerization plasticity, e.g., with HER3. Such RTK dimerization patterns affect responses to EGFR and HER2 targeting inhibitors in ESCC and EAC cells in vitro and hence may influence future prediction for particularly HER2-targeting inhibitors in EACs.
What's New?
Receptor tyrosine kinases (RTKs) of the EGFR family represent valuable therapeutic targets for esophageal squamous cell carcinomas (ESCCs) and/or esophageal adenocarcinomas (EACs). However, there is a lack of studies investigating the cellular mechanisms of action of RTK inhibitors. This study reveals for the first time dimerization of EGFR, HER2 and HER3 in ESCC and EAC in vitro and in situ. EGFR and HER2 overexpression predominantly results in homodimers in ESCCs and EACs, respectively. HER3 is highly expressed in EACs, where it dimerizes with HER2. This suggests previously unconsidered mechanisms of action and may inform response prediction of HER2-targeting inhibitors in EACs.
(C) 2014 John Wiley & Sons, Ltd
|
Author Keywords: | esophageal carcinomas; EGFR/HER2/HER3-dimers; clinical inhibitors.
|
References: | 1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2001; 2:127-37.
2. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer, 2006; 6:714-27.
3. Lassmann S, Werner M. Predictive pathology in routine diagnostics of solid tumors. Histol Histopathol, 2012; 27:289-96.
4. Gabbert HE, Shimoda T, Hainaut P, et al. Squamous cell carcinoma of the oesophagus. In: Hamilton SR, Aalton LA, Kleihues P, et al., eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000. 11-9.
5. Werner M, Flejou JF, Hainaut P, et al. Adenocarcinoma of the oesophagus. In: Hamilton SR, Aalton LA, Kleihues P, et al., eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000. 20-6.
6. Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet, 2013; 381:400-12.
7. Walch A, Bink K, Hutzler P, et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol, 2000; 31:1332-4.
8. Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res, 2012; 18:546-54.
9. Yamamoto Y, Yamai H, Seike J, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Ann Surg Oncol, 2012; 19:757-65.
10. Marx AH, Zielinski M, Kowitz CM, et al. Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology, 2010; 57:418-26.
11. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol, 2011; 8:492-503.
12. Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer, 2006; 118:1173-80.
13. Reichelt U, Duesedau P, Tsourlakis M, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol, 2007; 20:120-9.
14. Sato-Kuwabara Y, Neves JI, Fregnani JH, et al. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using fluorescence in situ hybridization (FISH) and immunohistochemistry. BMC Cancer, 2009; 9:6.
15. Cronin J, McAdam E, Danikas A, et al. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am J Gastroenterol, 2011; 106:46-56.
16. Paterson AL, O'Donovan M, Provenzano E, et al. Characterisation of the timing and prevalence of receptor tyrosine kinase expression changes in esophageal carcinogenesis. J Pathol, 2013; 230:118-28.
17. Wei Q, Chen L, Sheng L, et al. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol, 2007; 31:493-9.
18. Yoon HH, Sukov WR, Shi Q, et al. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer, 2014; 120:415-24.
19. Sutter AP, Hopfner M, Huether A, et al. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer, 2006; 118:1814-22.
20. Hara F, Aoe M, Doihara H, et al. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett, 2005; 226:37-47.
21. Mimura K, Kono K, Maruyama T, et al. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer, 2011; 129:2408-16.
22. Milano F, Guarriera M, Rygiel AM, et al. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS One, 2010; 5:e12424.
23. Hong J, Katsha A, Lu P, et al. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma. Cancer Res, 2012; 72:4504-14.
24. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol, 2006; 24:1612-19.
25. Ilson DH, Kelsen D, Shah M, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer, 2011; 117:1409-14.
26. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 2009; 20:1667-73.
27. Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol, 2011; 22:1367-73.
28. Luber B, Deplazes J, Keller G, et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer, 2011; 11:509.
29. Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol, 2013; 14:490-9.
30. Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol, 2013; 14:481-9.
31. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010; 376:687-97.
32. Gravalos C, Gomez-Martin C, Rivera F, et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol, 2011; 13:179-84.
33. Kwak EL, Jankowski J, Thayer SP, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res, 2006; 12:4283-7.
34. Shigaki H, Baba Y, Watanabe M, et al. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review. Ann Surg Oncol, 2013; 20 (Suppl. 3):S485-S491.
35. Yamashita-Kashima Y, Iijima S, Yorozu K, et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res, 2011; 17:5060-70.
36. Choi BK, Fan X, Deng H, et al. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells. Cancer Med, 2012; 1:28-38.
37. Spears M, Taylor KJ, Munro AF, et al. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat, 2012; 132:463-70.
38. DeFazio-Eli L, Strommen K, Dao-Pick T, et al. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res, 2011; 13:R44.
39. Ghosh R, Narasanna A, Wang SE, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res, 2011; 71:1871-82.
40. Boonstra JJ, van Marion R, Beer DG, et al. Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst, 2010; 102:271-4.
41. Fichter CD, Herz C, Munch C, et al. Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells. BMC Cell Biol, 2011; 12:13.
42. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch, 2010; 457:299-307.
43. Zhang XL, Yang YS, Xu DP, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg, 2009; 33:2112-18.
44. Laux I, Jain A, Singh S, et al. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer, 2006; 94:85-92.
45. Kawaguchi Y, Kono K, Mimura K, et al. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer, 2007; 97:494-501.
46. Paterson AL, Shannon NB, Lao-Sirieix P, et al. A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut, 2013; 62:1415-24.
47. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res, 2009; 15:7479-91.
48. Beji A, Horst D, Engel J, et al. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res, 2012; 18:956-68.
49. Huang S, Li C, Armstrong EA, et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res, 2013; 73:824-33.
|
Language: | English.
|
Document Type: | Cancer Cell Biology.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0020-7136
|
DOI Number: | https://dx.doi.org/10.1002/ijc.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|